BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tarceva erlotinib: Additional Phase II data

Researchers at the M.D. Anderson Cancer Center reported additional data from a subgroup of 101 stage IV NSCLC patients who had gene expression profiles obtained from pretreatment core needle biopsies in the adaptive, open-label, U.S. Phase II BATTLE trial showing that 2 gene signatures were predictive of disease control with Tarceva in patients with wild-type EGFR and K-Ras. An epithelial-mesenchymal transition (EMT) signature using 4 genes showed that Tarceva had a significantly higher 8-week DCR in tumors with an epithelial phenotype vs. a mesenchymal phenotype (64% vs. 10%, p=0.02). A new 5-gene signature also predicted DCR at 8 weeks (83% vs. 0%. p<0.001) and PFS (12.5...

Read the full 520 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >